Influence of Dose, Cigarette Smoking, Age, Sex, and Metabolic Activity on Plasma Clozapine Concentrations: A Predictive Model and Nomograms to Aid Clozapine Dose Adjustment and to Assess Compliance in Individual Patients

@article{RostamiHodjegan2004InfluenceOD,
  title={Influence of Dose, Cigarette Smoking, Age, Sex, and Metabolic Activity on Plasma Clozapine Concentrations: A Predictive Model and Nomograms to Aid Clozapine Dose Adjustment and to Assess Compliance in Individual Patients},
  author={Amin Rostami-Hodjegan and Ajmal M Amin and Edgar Pathrose Spencer and Martin S. Lennard and Geoffrey T Tucker and R. J. Flanagan},
  journal={Journal of Clinical Psychopharmacology},
  year={2004},
  volume={24},
  pages={70-78}
}
Abstract: The measurement of plasma clozapine concentrations is useful in assessing compliance, optimizing therapy, and minimizing toxicity. We measured plasma clozapine and norclozapine (N-desmethylclozapine) concentrations in samples from 3782 patients (2648 male, 1127 female). No clozapine was detected in 291 samples (227 patients, median prescribed dose 300 mg/d). In 4963 (50.2 %) samples (2222 patients); plasma clozapine concentration ranged from 10 to 350 ng/mL. Step-wise backward… 

Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations

Findings suggest the importance of clozapine TDM due to misunderstood inter- and/or intraindividual variability or misestimated partial therapeutic compliance in patients diagnosed with schizophrenia or schizoaffective disorder.

Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables.

A possible interaction between taking valproic acid and smoking, which modifies plasma clozapine concentrations is described, by estimating the effect sizes of other compounds on plasmaClozapines concentrations after correcting for confounders, and by providing dose-correction factors for clinicians.

Sex differences in plasma clozapine and norclozapine concentrations in clinical practice and in relation to body mass index and plasma glucose concentrations: a retrospective survey

It is shown that mean BMI and blood glucose concentrations are higher in women prescribed clozapine than in men, and women also tended to attain higher plasma clozAPine concentrations than men.

Plasma Clozapine, Norclozapine, and the Clozapine:Norclozapine Ratio in Relation to Prescribed Dose and Other Factors: Data From a Therapeutic Drug Monitoring Service, 1993–2007

Analysis of the plasma clozapine:norclozabine ratio by clozAPine concentration provides clear evidence that clozamine N-demethylation becomes saturated at higher plasma clazapine concentrations and adds urgency to the requirement for dose adjustment should smoking habit change.

Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia.

Among the patient-related factors investigated, only gender was significant in affecting CLZ concentrations in Chinese patients with schizophrenia, with female patients having higher levels.

Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients

The present study suggests that decreased absolute and dose-adjusted serum concentrations of clozapine were associated with clozAPine discontinuation, and this may indicate a pharmacokinetic mechanism underlying the risk ofClozapines discontinuation.

The Effect of Body Weight Changes on Total Plasma Clozapine Concentrations Determined by Applying a Statistical Model to the Data From a Double-Blind Trial

Weight increases during clozapine treatment, which probably reflect increases in fat tissue, were associated with increases in total plasma concentrations, and it seems likely that clozabine may deposit in body fat and that this may decrease clozAPine clearance.

Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients—a genome-wide association study adjusting for smoking habits

A novel variant in the NFIB gene was identified associated with reduced CLZ levels and increased risk of subtherapeutic serum concentrations, which warrants testing of clinical relevance of screening for this gene variant, and also experimental studies to investigate the biological mechanisms of NFIB involvement in CLZ pharmacokinetics.

Metabolite Profiling of Clozapine in Patients Switching Versus Maintaining Treatment

A significantly reduced 5N-glucuronidation phenotype is found in patients switching from clozapine at therapeutic serum concentrations (>1070 nmol/L) to other antipsychotic drugs, which may indicate that glucuronidation, as a potential detoxification mechanism, is related to clozAPine tolerability.

Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia

The one-compartment pharmacokinetic model with mixture error could best describe the concentration-time profiles of clozapine and norclozAPine and this model can be used in individualized drug dosing and therapeutic drug monitoring.
...

References

SHOWING 1-10 OF 64 REFERENCES

Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age

A considerable variation of clozapine plasma levels at a given dose depending on a number of factors should be taken into consideration for efficient therapy with the lowest possible dose.

CYP1A2 Activity as Measured by a Caffeine Test Predicts Clozapine and Active Metabolite Norclozapine Steady-State Concentration in Patients With Schizophrenia

CYP1A2 is one of the important contributors to disposition of clozapine during multiple-dose treatment and appears to be subsequent to the formation of norclozAPine, hitherto less recognized quantitatively important alternate disposition routes, or both.

Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram

CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.

CYP1A2 is one of the important contributors to disposition of clozapine during multiple-dose treatment and appears to be subsequent to the formation of norclozAPine, hitherto less recognized quantitatively important alternate disposition routes, or both.

Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking.

The mean doses of clozapine after 6 months of treatment and at the time of blood sampling were not significantly different in 30 responders and 29 nonresponders to clazapine, on the basis of the decrease in BPRS Total scores, whereas the concentrations in plasma in clozAPine of norclozapines and the sum of their concentrations were significantly higher in responders.

Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients Influence of patient-related variables

The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement.

The results show that clozapine clearance and daily dose requirement are strongly associated with smoking behaviour, while the CYP1A2 genetic polymorphism seems to have no significant clinical effect.

Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients

No clinically meaningful pattern in serum parameters could be identified that differentiates responders from non-responders and clozapine TDM seems ineffective for predicting clinical response, indicating a possible link between CYP activity and response to clozAPine that is not mediated through differences in serum concentrations.

Effect of caffeine on clozapine pharmacokinetics in healthy volunteers.

It is suggested that caffeine in daily doses of 400-1000 mg inhibits the metabolism of clozapine to an extent that might be clinically significant in certain individuals.

Relation of Blood Counts during Clozapine Treatment to Serum Concentrations of Clozapine and Nor-Clozapine

The mechanism of clozapine-induced hematotoxicity at the therapeutic dosage range is probably not by direct toxicity of clazapine or nor-clozapines to the blood cells or their precursors, but the formation of the cytotoxic nitrenium compound from clozAPine by neutrophils may be necessary.
...